Economic analysis of Noqturina® (oral lyophilisate) use in the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2018, Vol 2, Issue 2
Abstract
Introduction: Nocturia relates to the need to urinate at night when micturition was preceded by sleep and immediately followed by a period of sleep. The aim of this analysis is to examine the cost-effectiveness of desmopressin at a dose of 25 μg oral lyophilisate for women and 50 μg oral lyophilisate for men (DDAVP) in comparison to the best supportive care (BSC) used in Polish clinical practice in the treatment of nocturia (≥2 nocturnal micturition) caused by idiopathic nocturnal polyuria. Methods: The economic analysis uses a model combining the aspects of the partitioned-survival model and state-transition model (STM). The projection was carried out over a 30-year time horizon, which corresponds to 120 quarterly modelling cycles. The costs were calculated from a common perspective, including expenses incurred by the public payer (Narodowy Fundusz Zdrowia, National Health Found) and expenses incurred by the patient. Health effects of medical technologies have been estimated on the basis of unit data from CS40 and CS41 studies. The literature, statistical databases and information provided by clinical experts were used to develop the remaining input data, including utility. Results: The ICER for DDAVP + BSC compared to BSC was 56.1 kPLN (13.0 kEUR) and is below the cost-effectiveness threshold in force in Poland (135.5 kPLN; 31.2 kEUR). The multi-directional sensitivity analysis shows a profitability rate of 98.6%. Conclusions: The economic model shows that the addition of orodispersible DDAVP to standard treatment allows reducing the expected number of nocturnal micturition, improving the quality of life and reducing the number of injuries and fractures in the group of patients with nocturia caused by idiopathic nocturnal polyuria. Considering the total direct medical costs of treatment, desmopressin administered at a dose of 25 μg for women and 50 μg for men is a cost-effective therapy when added to the BSC.
Authors and Affiliations
Maciej Dzik, Grzegorz Binowski, Piotr Chłosta, Jakub Dobruch, Paweł Miotła, Tomasz Rechberger, Adam Bierut
Keywords
Related Articles
- EP ID EP532128
- DOI 10.7365/JHPOR.2018.2.1
- Views 52
- Downloads 0
Aging society: organization of long-term care for the elderly in Poland.
Background: Aging society is one of the main challenges of the organization and provision of health care in XXI century. In 2030 more than one third of Polish population will be older than 65 years old and every tenth...
Cost-effectiveness analysis of methods of diagnosis of tb infection in russian regions by use of recombinant tb allergen in children and adolescents
Background. Russia is among the countries with a high burden of TB. A new diagnostic method for TB has been developed, called ‘recombinant tuberculosis allergen’ or RTA (Diaskintest®), which has a similar cost and method...
Optimization of approaches to the treatment of metastatic colorectal cancer wild-type gene KRAS
The results of the literature review of drug use for the treatment of metastatic colorectal cancer (mCRC) are presented. Analysis of the data showed that cetuximab (Erbitux) and panitumumab (Vectibix) are effective drugs...
Idiopathic Pulmonary Fibrosis as a Challenge for the Polish Healthcare System
Idiopathic pulmonary fibrosis (IPF) is a rare disease characterised by age-dependent incidence, unclear aetiology and progressive course. Given the complexity of the diagnostic pathway and limited therapeutic options, an...
Multiple Criteria Decision Analysis (MCDA) for Health Care Decision Making – overview of guidelines
Multidimensional context of decision making in health care implies the need for structured approach which can be supported by Multiple Criteria Decision Analysis (MCDA). Despite the fact that MCDA is more widely discuss...